

Jun Gong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1779172/publications.pdf>

Version: 2024-02-01

92
papers

2,559
citations

331642

21
h-index

377849

34
g-index

93
all docs

93
docs citations

93
times ranked

5360
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis. <i>Pancreatology</i> , 2022, 22, 92-97.	1.1	4
2	Retrospective study of survival outcomes in patients with hereditary pathogenic and variants of unknown significance mutations in pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 616-616.	1.6	0
3	Real-world clinical outcomes and molecular features of lung-specific and liver-specific metastases in pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 532-532.	1.6	0
4	A phase I study of first-line L-glutamine (Gln) with gemcitabine (gem) and nab-paclitaxel (nab-p) in advanced pancreatic cancer (GlutaPanc).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS636-TPS636.	1.6	0
5	Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 511-524.	2.0	1
6	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. <i>Drugs</i> , 2022, 82, 439-453.	10.9	3
7	Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2704-2714.	7.0	57
8	Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 100.	1.0	4
9	Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 23.	2.5	1
10	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	7.3	18
11	Impact of site-specific metastases on survival outcomes in pancreatic adenocarcinoma (PDAC) patients: A national analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16270-e16270.	1.6	0
12	Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4192-TPS4192.	1.6	1
13	Gut microbiome and pancreatic cancer cachexia: An evolving relationship. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1218-1226.	2.0	3
14	A National Cancer Database (NCDB) analysis of the impact of nonmetastatic colon cancer sidedness on survival.. <i>Journal of Clinical Oncology</i> , 2021, 39, 139-139.	1.6	0
15	Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations. <i>Cancers</i> , 2021, 13, 1706.	3.7	19
16	Immunotherapy Updates in Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2164.	3.7	14
17	Bridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1538-1538.	1.6	0
18	Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. <i>Cancer Medicine</i> , 2021, 10, 5671-5680.	2.8	2

#	ARTICLE	IF	CITATIONS
19	Disparities and survival in newly diagnosed gastric cancer in Hispanic patients in the United States: a propensity score matched analysis. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1308-1325.	1.4	4
20	Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4819-4832.	2.0	11
21	Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4547.	3.7	12
22	Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification. <i>Oncology</i> , 2021, 35, 528-535.	0.5	0
23	Racial differences in tumor biology and treatment of gastric cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2021, 39, 174-174.	1.6	3
24	Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1959-1968.	7.3	17
25	Advances in Pancreatic Ductal Adenocarcinoma Treatment. <i>Cancers</i> , 2021, 13, 5510.	3.7	28
26	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. <i>Cancer Research</i> , 2021, 81, 6273-6280.	0.9	30
27	An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer. <i>Oncology</i> , 2021, 35, 650.	0.5	0
28	A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138432.	5.9	8
29	Raynaud's Phenomenon From PD-1 Immune Checkpoint Inhibition. <i>JCO Oncology Practice</i> , 2020, 16, 701-702.	2.9	2
30	Novel <i>ALK</i> Fusion, <i>PPFIBP1-ALK</i> , in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib. <i>JCO Precision Oncology</i> , 2020, 4, 865-870.	3.0	15
31	Fecal elastase, an assay for exocrine pancreatic insufficiency, has clinical utility in patients with pancreatic ductal adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096431.	3.2	1
32	Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. <i>Cancers</i> , 2020, 12, 1168.	3.7	13
33	Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 4525-4532.	1.5	13
34	Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 425-428.	1.9	7
35	Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2020, 4, 514-519.	3.0	1
36	The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 581.	2.8	1

#	ARTICLE	IF	CITATIONS
37	Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 1459-1462.	1.1	11
38	A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4634-4634.	1.6	3
39	A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS780-TPS780.	1.6	1
40	Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. <i>World Journal of Gastrointestinal Surgery</i> , 2020, 12, 377-389.	1.5	3
41	Socioeconomic disparities and outcomes in midgut neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 613-613.	1.6	6
42	A radiopaque polymer hydrogel as an irreversible electroporation compatible fiducial marker for pancreas stereotactic body radiotherapy. <i>Journal of Radiosurgery and SBRT</i> , 2020, 7, 165-167.	0.2	0
43	Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. <i>Advances in Radiation Oncology</i> , 2019, 4, 513-519.	1.2	12
44	The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. <i>Clinical and Translational Medicine</i> , 2019, 8, 9.	4.0	80
45	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. <i>Clinical Colorectal Cancer</i> , 2019, 18, 307-309.	2.3	6
46	Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 63-63.	3.0	12
47	Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e454-e460.	1.9	14
48	Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. <i>Cancers</i> , 2019, 11, 841.	3.7	68
49	Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. <i>BMC Cancer</i> , 2019, 19, 548.	2.6	34
50	Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. <i>Targeted Oncology</i> , 2019, 14, 269-283.	3.6	8
51	Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma. <i>Case Reports in Urology</i> , 2019, 2019, 1-4.	0.3	17
52	Pancreatic cancer "mismatch"™ in Lynch syndrome. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000274.	2.7	6
53	A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction. <i>Oncologist</i> , 2019, 24, 1137-1145.	3.7	2
54	Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. <i>Oncotarget</i> , 2019, 10, 6260-6268.	1.8	6

#	ARTICLE	IF	CITATIONS
55	When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer?. <i>Annals of Translational Medicine</i> , 2019, 7, S35-S35.	1.7	1
56	PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1026-1030.	4.9	12
57	Multiplatform profiling of pancreatic neuroendocrine tumors (PanNETs) identifies novel co-occurring pathogenic alterations and associations with clinicopathologic factors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 211-211.	1.6	0
58	Patient and physician preferences for NIH PROMIS patient-reported outcome (PRO) domains in pancreatic ductal adenocarcinoma (PDA).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15721-e15721.	1.6	0
59	A single institution experience with palbociclib toxicity requiring dose modifications. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 381-387.	2.5	29
60	Managing Patients With Relapsed Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 359-366.	2.5	38
61	Immune profiling of microsatellite instability-high and polymerase δ (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 404-415.	1.4	49
62	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. <i>Clinical and Translational Medicine</i> , 2018, 7, 32.	4.0	29
63	Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 560-572.	1.4	9
64	Value-based genomics. <i>Oncotarget</i> , 2018, 9, 15792-15815.	1.8	46
65	Influence of an International Consensus Conference on Practice Patterns in Advanced Prostate Cancer. <i>European Urology</i> , 2018, 74, 239-240.	1.9	0
66	Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 777-786.	4.3	37
67	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
68	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
69	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. <i>World Journal of Gastroenterology</i> , 2018, 24, 2686-2697.	3.3	23
70	Statins and pancreatic cancer. <i>Oncology Letters</i> , 2017, 13, 1035-1040.	1.8	40
71	Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. <i>Clinical Therapeutics</i> , 2017, 39, 2135-2145.	2.5	12
72	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. <i>Oncotarget</i> , 2017, 8, 42198-42213.	1.8	49

#	ARTICLE	IF	CITATIONS
73	A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres [®] versus SIR-Spheres [®] alone in chemotherapy-resistant colorectal cancer liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 608-613.	1.4	3
74	Systemic Therapy for Non-clear Cell Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 337-342.	3.8	19
75	Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 314-323.	1.4	5
76	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017, 8, 79750-79760.	1.8	12
77	MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. <i>Anticancer Research</i> , 2017, 37, 2831-2838.	1.1	11
78	Tumor mutational burden of microsatellite stable metastatic colorectal tumors by patient factors and KRAS, BRAF, and PIK3CA mutation status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 627-627.	1.6	1
79	RAS and BRAF in metastatic colorectal cancer management. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 687-704.	1.4	56
80	Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. <i>World Journal of Methodology</i> , 2016, 6, 25.	3.5	101
81	Targeting mTOR in Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2016, 6, 99.	2.8	33
82	Metastasis in renal cell carcinoma: Biology and implications for therapy. <i>Asian Journal of Urology</i> , 2016, 3, 286-292.	1.2	107
83	Advances in treatment of metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2016, 26, 439-446.	1.8	9
84	The state of regional therapy in the management of metastatic colorectal cancer to the liver. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 229-245.	2.4	5
85	Meta-analyses of treatment standards for pancreatic cancer. <i>Molecular and Clinical Oncology</i> , 2016, 4, 315-325.	1.0	31
86	The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. <i>Targeted Oncology</i> , 2016, 11, 447-467.	3.6	49
87	A Pilot Study of the Impact of a Single Dose of Zolendronic acid on Biomarkers in Breast Cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23248-e23248.	1.6	0
88	Adnectin-Targeted Inhibitors: Rationale and Results. <i>Current Oncology Reports</i> , 2015, 17, 35.	4.0	14
89	Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells. <i>Frontiers in Oncology</i> , 2014, 4, 167.	2.8	56
90	Alopecia areata as a paraneoplastic syndrome of Hodgkin's lymphoma: A case report. <i>Molecular and Clinical Oncology</i> , 2014, 2, 596-598.	1.0	9

#	ARTICLE	IF	CITATIONS
91	A Case of Cutaneous Plasmablastic Lymphoma in HIV/AIDS with Disseminated <i>Cryptococcus</i> . Case Reports in Oncological Medicine, 2013, 2013, 1-4.	0.3	10
92	A Rare Case of Primary Gastric HIV-Associated Peripheral T-Cell Lymphoma: Relapsed Disease Treated With Pemetrexed. World Journal of Oncology, 2013, 4, 217-220.	1.5	1